TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05917080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Manual Therapy: Manual therapy is the use of hands-on techniques to evaluate, treat, and improve the status of Neuro-musculoskeletal conditions.~Augmented Low-Dye Taping: Augmented Low-Dye taping is designed to off-load the plantar fascia \& applied below the ankle and is hypothesised to generate a supinating force that controls the amount of pronation at the subtalar joint.~Neuromuscular Exercises: Neuromuscular training could be defined as training enhancing unconscious motor responses by stimulating both afferent signals and central mechanisms responsible for dynamic joint control.~Strengthening Exercises:The strengthening of the muscles promotes better overall functioning of the foot and thereby can help to take some of the tension out of the fascia.~Stretching exercises:Static stretching is defined as passively stretching a given muscle-tendon unit by slowly placing it maximal position of stretch and sustaining it there for an extended period of time.

Intervention type: OTHER
Group type: OTHER
Intervention: Manual Therapy
Description: Manual Therapy: Manual therapy is the use of hands-on techniques to evaluate, treat, and improve the status of Neuro-musculoskeletal conditions.~Augmented Low-Dye Taping: Augmented Low-Dye taping is designed to off-load the plantar fascia \& applied below the ankle and is hypothesised to generate a supinating force that controls the amount of pronation at the subtalar joint.~Neuromuscular Exercises: Neuromuscular training could be defined as training enhancing unconscious motor responses by stimulating both afferent signals and central mechanisms responsible for dynamic joint control.~Strengthening Exercises:The strengthening of the muscles promotes better overall functioning of the foot and thereby can help to take some of the tension out of the fascia.~Stretching exercises:Static stretching is defined as passively stretching a given muscle-tendon unit by slowly placing it maximal position of stretch and sustaining it there for an extended period of time.
Study: NCT06638866

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pancreatic imaging AI model
Description: Subjects identified with pancreatic lesions by the AI model, which include PDAC and non-PDAC subtypes, will be required to undergo questionnaire, blood tests (including CA19-9, CA125, CEA, etc.) and further imaging examinations (including contrast CT, MRI, EUS, etc.) to confirm the final status of the pancreatic lesion.
Study: NCT06182748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training on eccentric ergocycle
Description: Subjects will train on eccentric ergocycles. In eccentric cycling, pedals push against the user's feet in the opposite direction, user has to slow down pedals and quadriceps muscles lengthen during contraction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training on concentric ergocycle
Description: Subjects will train on regular concentric ergocycles. In concentric cycling, quadriceps contract to push pedals.
Study: NCT04679649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual spinal mobilisation physiotherapy
Description: Manual spinal mobilisation is a physiotherapy technique to improve spinal mobility by gently applying pressure manually on the each segmental vertebrae by hands-on treatment of a physiotherapist.
Study: NCT06367998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin oral intake from the day before surgery to six weeks postoperatively
Study: NCT05245292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Intravenous infusion of 3BNC117-LS at 30 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Intravenous infusion of 10-1074-LS at 10 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N803
Description: Subcutaneous injections of N803 at 6 mcg/kg
Study: NCT05485506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal exercise program
Description: Running technical drills: pogo, askip, dribble, scissor, etc. Exercises for lumbopelvic stabilization: mobility exercises, hip thrust, dead lift, lunge to skip.~Resisted sprints by using a sled: resistance leading to a 60% and 30% of optimal load (previously calculated)
Study: NCT06188923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone
Description: Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as active comparator, except placebo dispensed
Study: NCT05115968

Intervention type: PROCEDURE
Intervention: Tonsillectomy
Description: Subjects who are diagnosed to have OSA with adeontonsillar enlargement will undergo adenotonsillectomy if it is clinically indicated. Adenotonsillar tissue will be obtained for single cell sequencing. Controls will be non-OSA subjects (with PSG OAHI \<1/hour) who undergo adenotonsillectomy for other reasons such as recurrent tonsillitis.

Intervention type: PROCEDURE
Intervention: Tonsillectomy
Description: Subjects who are diagnosed to have OSA with adeontonsillar enlargement will undergo adenotonsillectomy if it is clinically indicated. Adenotonsillar tissue will be obtained for single cell sequencing. Controls will be non-OSA subjects (with PSG OAHI \<1/hour) who undergo adenotonsillectomy for other reasons such as recurrent tonsillitis.
Study: NCT06148077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: 3 times a week, for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor control exercises
Description: 3 times a week, for 6 weeks.
Study: NCT04667507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Ophthalmic implant
Description: Dexamethasone ophthalmic insert 0.4 mg for intracanalicular use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Ophthalmic implant
Description: Dexamethasone ophthalmic insert 0.4 mg for intracanalicular use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Ophthalmic implant
Description: Dexamethasone ophthalmic insert 0.4 mg for intracanalicular use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Ophthalmic implant
Description: Dexamethasone ophthalmic insert 0.4 mg for intracanalicular use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Ophthalmic implant
Description: Dexamethasone ophthalmic insert 0.4 mg for intracanalicular use
Study: NCT04557293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Description: Treatment of Obstructive sleep apnoea syndrome with CPAP
Study: NCT06362096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab+pyrotinib+taxene
Description: Trastuzumab (first cycle 8mg/Kg, subsequent 6mg/Kg, iv, q3w) Pyrrotinib \* po, qd, q3w The first cycle 240mg+ montmorillonite powder, the second cycle 320mg+ montmorillonite powder prevention Subsequent cycle 400mg+\* montmorillonite powder used when necessary taxenes
Study: NCT06562556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the breather device
Description: investigate the effect of the breather device on ventilatory effort and in patients with myogenic temporomandibular joint disorders

Intervention type: OTHER
Group type: OTHER
Intervention: conventional exercise program
Description: -Therapeutic Ultrasound (US): Ultrasound therapy will be applied at the site of pain over the TMJ area with Frequency: 1 MHz, Mode: continuous, Duration: 6 min. each session 2-Myofascial release for masticatory muscles 3-The self-exercise Self exercise: include simplified myo-functional therapy. 10 repetitions, three: five times per day 4-Techniques to correct deglutition: swallowing a small amount of water and speaking while holding a semi-hard small object between the dental arches 5-Relaxation exercise of Masticator Muscle:10 repetitions, three.~6-Strain-counterstain (SCS): applied on the tender or trigger points of neck muscles on improving pain and pressure pain sensitivity in neck muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional exercise program
Description: -Therapeutic Ultrasound (US): Ultrasound therapy will be applied at the site of pain over the TMJ area with Frequency: 1 MHz, Mode: continuous, Duration: 6 min. each session 2-Myofascial release for masticatory muscles 3-The self-exercise Self exercise: include simplified myo-functional therapy. 10 repetitions, three: five times per day 4-Techniques to correct deglutition: swallowing a small amount of water and speaking while holding a semi-hard small object between the dental arches 5-Relaxation exercise of Masticator Muscle:10 repetitions, three.~6-Strain-counterstain (SCS): applied on the tender or trigger points of neck muscles on improving pain and pressure pain sensitivity in neck muscles
Study: NCT06018363

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic B7H3 CAR-γδT cell
Description: Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^7 cells) , dose 2 (3 × 10\^7 cells), dose 3 (1× 10\^8 cells); Phase 2 : dose of RP2D.
Study: NCT06274281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Telerehabilitation
Description: The 5-day rehabilitation program will consist of exercises to re-establish standard movement patterns within a multidisciplinary etiological framework, according to a validated rehabilitation protocol for FMDs. Treatment will be tailored to the needs of each patient, following general treatment principles in physiotherapy for FMDs.~Telemedicine sessions: the patient will perform specific exercises under the supervision of a qualified physiotherapist to provide feedback on the execution and adapt the treatment according to clinical changes/improvements.~Wearable devices: each patient in the experimental group will receive 2 wearable sensors (Axivity AX3,) for monitoring of movement data (i.e., activity level, number of steps, distance travelled) during daylife activities and rehabilitation sessions. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The 5-day rehabilitation program will be the same as the telemedicine group. A self-management paper log will be given to the patient at the end of the 5-day rehabilitation program. It will include goals, activity plans, and strategies to be used for retraining movements and redirecting attention. Videos stored on the patients' digital device (i.e., tablet, mobile) will include exercises demonstration and execution and strategies to retrain movements. Patients will be encouraged to perform the self-management plan at home on their own (or with their caregivers' help) which will be reported in a paper log and video recorded. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
Study: NCT05641298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fusidate
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study: NCT05278624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast Cream
Description: Topical Cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Roflumilast Cream
Description: Topical Cream
Study: NCT05396326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teysuno
Description: Oral S-1, 40mg-60mg bid, day 1-14 for four 21-day cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial arterial chemoinfusion and embolism (TACiE)
Description: In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1, if applicable.
Study: NCT05602480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Description: 0.5mL, Intramuscular
Study: NCT05294133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: physical activity
Study: NCT05409300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBIBP-CorV
Description: Inactivated COVID19 vaccine, adjuvanted with aluminum hydroxide
Study: NCT05214339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab
Description: The patient will receive Hepatic Arterial Infusion(mFOLFOX7) on the first day, and intravenous infusion of Bevacizumab on the 4th day, and intravenous infusion of Sintilimab on the 25th day. The intervention is repeated every 3 weeks.
Study: NCT06399718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular Injections
Study: NCT05655260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparison of chemotherapy vs. chemoradiotherapy
Description: Chemotherapy (paclitaxel-carboplatin) vs. chemoradiotherapy (paclitaxel-carboplatin followed by whole pelvic radiotherapy)~Patients assigned to chemotherapy receive paclitaxel (175 mg/m2) and carboplatin (area under curve, 5) every 3 weeks for 6 cycles. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparison of VBT vs. WPRT
Description: Vaginal brachytherapy vs. whole pelvic radiotherapy~Patients randomized to vaginal brachytherapy receive cuff brachytherapy at 21 Gy in 3 fractions of 7 Gy at 0.5 cm depth. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparison of VBT vs. WPRT
Description: Vaginal brachytherapy vs. whole pelvic radiotherapy~Patients randomized to vaginal brachytherapy receive cuff brachytherapy at 21 Gy in 3 fractions of 7 Gy at 0.5 cm depth. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions).
Study: NCT06442969

Intervention type: OTHER
Group type: OTHER
Intervention: Education and resources provided by community health workers
Description: The intervention will consist of implementing existing tools provided by EPA's Design for the Environment program, CalOSHA and NIOSH sector-specific guidance for agricultural workers, the Imperial County Department of Public Health and materials from California Department of Toxics Substances Control. The investigators will utilize and adjust existing educational tools such as the Heat Illness Prevention plan developed by CalOSHA. In addition to the educational materials, the investigators will give each farmworker cooling working gear to be worn during their work-shift with (specialized clothes that has been used in other occupational settings). The investigators will provide all participants with a low-cost fan filter, known as Corsi-Rosenthal box built jointly by the community health/research team to reduce chemicals at home, and a small A/C unit to reduce heat stress.
Study: NCT04624074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Marijuana Check Up
Description: Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.
Study: NCT05364073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib tablet
Study: NCT06035328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat (Four times per week)
Description: Case wheat allergy that on four times/week dose during one year maintenance phase of wheat OIT
Study: NCT04577560

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: First polar body biopsy in MII oocytes
Description: Since PBs are by-products of the meiotic division of the oocyte and are not required for fertilization and subsequent embryo development, they can be removed to assess exclusively maternal chromosomal information without harming the embryo integrity. As previously described, PB biopsy does not impact the morphokinetic parameters of the embryo development and can be safely applied without the risk of impairing the reproductive potential of the embryo.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PGT-A blastocyst
Description: preimplantation genetic screening for aneuploidies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PGT-A blastocyst
Description: preimplantation genetic screening for aneuploidies
Study: NCT04720053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable brain sensing wellness device headband system
Description: Brain sensing headband that measures brain activity by detecting electrical impulses created by the brain.
Study: NCT05093075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Plasma Exchange
Description: TPE procedures will be performed using a Spectra Optia ® apheresis machine (Terumo BCT, Lakewood, USA) according to usual-care procedures for apheresis. Venous access for the TPE procedures will be obtained through a double lumen dialysis catheter to provide adequate flow rates required for TPE. Regional citrate anticoagulation will be used for anticoagulation within the apheresis circuit. One to two grams of calcium chloride will be infused as per standard during TPE to prevent symptomatic hypocalcemia. Plasma volume will be calculated as per a standard formula whereby estimated plasma volume (in liters) = 0.07 x weight (kg) x (1 - hematocrit). In patients on dialysis, dialysis will be interrupted for the duration of the procedure. Antibiotics will be given after TPE to avoid clearance of the antibiotics. On the first day of TPE, a repeat dose of antibiotics will be administered after completion of TPE. Nurse clinicians trained in TPE will perform the TPE procedures.
Study: NCT04420845

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes Self-Management and Support (DSMES) and Sleep Hygiene Education and Support (SHES)
Description: SHES outlines the importance of sleep for people with type 2 diabetes mellitus and provide practical information and guidance about sleep habits. Specifically, the focus will be on: avoiding consumption of caffeine, nicotine, alcohol; avoiding use of light emitting devices before bedtime; avoiding excessive intake of fluids or heavy meals before bedtime; promoting regulation of light, noise, and temperature in the bedroom; timing of and importance of exercise; maintaining consistent sleep and wake times; establishing a pre-bedtime routine; and managing stress.
Study: NCT06340945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided thermal ablation
Description: microwave ablation, radio frequency ablation, laser ablation
Study: NCT05219331

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ventriculoperitoneal shunt
Description: Treatment oh hydrocephalus
Study: NCT05232318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leveling and alignment
Description: Root resorption comparison through the use of CBCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leveling and alignment
Description: Root resorption comparison through the use of CBCT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leveling and alignment
Description: Root resorption comparison through the use of CBCT
Study: NCT03984994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: 3 months of center-based, supervised treadmill exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise training
Description: 3 months of center-based, supervised treadmill exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: 3 months of center-based, supervise strength training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: 3 months of center-based, supervise strength training